中恒集团(600252) - 2025 Q3 - 季度财报

Financial Performance - The company's operating revenue for the third quarter was ¥497,081,271.12, a decrease of 3.65% compared to the same period last year[4] - The total profit for the third quarter was -¥16,674,934.43, with a year-to-date profit of ¥11,059,706.30, reflecting a significant increase of 1,266.89% year-on-year[4] - The net profit attributable to shareholders for the third quarter was -¥2,437,249.27, while the year-to-date net profit was ¥24,640,374.94, an increase of 119.61% compared to the previous year[4] - The basic and diluted earnings per share for the third quarter were both -¥0.0008, while the year-to-date figures were ¥0.0078, showing a year-on-year increase of 136.36%[4] - Total operating revenue for the first three quarters of 2025 was CNY 1,809,411,026.87, down from CNY 2,401,872,835.33 in the same period of 2024, representing a decrease of approximately 24.6%[26] - The net profit attributable to shareholders of the parent company for the first three quarters of 2025 was CNY 24,640,374.94, compared to CNY 11,220,044.44 in 2024, showing an increase of approximately 119.5%[25] - The company reported a total profit of CNY 11,059,706.30 for the first three quarters of 2025, a significant increase from CNY 809,116.89 in the previous year[24] - The total comprehensive income for the first three quarters of 2025 was CNY 41,197,411.17, down from CNY 228,751,560.29 in 2024, indicating a decrease of about 82.0%[25] Assets and Liabilities - Total assets at the end of the reporting period were ¥11,064,253,519.24, an increase of 0.78% from the end of the previous year[5] - The equity attributable to shareholders decreased to ¥5,799,508,176.13, down 3.71% from the previous year-end[5] - The company's total assets amounted to CNY 11,064,253,519.24, an increase from CNY 10,979,027,992.83 at the end of 2024[20] - Total liabilities as of September 30, 2025, were CNY 3,801,657,442.08, compared to CNY 3,464,282,597.71 at the end of 2024[21] - The company's equity attributable to shareholders was CNY 5,799,508,176.13, down from CNY 6,022,749,391.71 at the end of 2024[21] - Short-term borrowings increased to CNY 1,583,058,093.92 from CNY 1,304,042,585.63 year-over-year[21] Cash Flow - The net cash flow from operating activities for the year-to-date was -¥156,396,673.89, reflecting a decrease of 135.05% compared to the same period last year[4] - Net cash flow from operating activities for the first three quarters of 2025 was -CNY 156,396,673.89, compared to CNY 446,258,897.73 in 2024, indicating a significant decline[26] - The cash and cash equivalents at the end of the period were CNY 4,009,475,304.33, up from CNY 3,458,763,556.53 in 2024, reflecting an increase of about 15.9%[27] - The company incurred a net cash outflow from investing activities of -CNY 23,674,555.79 in 2025, compared to a net inflow of CNY 613,984,380.89 in 2024[27] - The company’s total cash inflow from financing activities was CNY 1,584,881,111.98, compared to CNY 1,075,294,376.79 in 2024, marking an increase of approximately 47.3%[27] Shareholder Information - The total number of common shareholders at the end of the reporting period is 118,959[11] - Guangxi Investment Group Co., Ltd. holds 859,343,587 shares, accounting for 26.89% of total shares[11] - The company plans to repurchase shares at a price not exceeding RMB 3.80 per share, with a total repurchase amount between RMB 300 million and RMB 500 million[13] - As of August 25, 2025, the company completed the repurchase of 118,117,197 shares, representing 3.5649% of the total share capital, with a total expenditure of RMB 301,021,106.92[14] Product Development and Market Position - The company’s subsidiary received a total of RMB 10,365,548.61 in compensation from the Zhaoqing High-tech Zone Land Reserve Center during the first three quarters of 2025[16] - The company’s subsidiary, Chongqing Laimei Pharmaceutical Co., Ltd., received approval for a supplementary application for an injectable drug, enhancing its market competitiveness[17] - Guangxi Zhongheng Innovation Pharmaceutical Research Co., Ltd. acquired a patent for a drug technology for treating chronic heart failure for RMB 55 million[17] - The company received drug registration certificates for two products, Nicorandil tablets (5mg) and Ketorolac tromethamine injection (1ml:30mg), enhancing its product line[18] - The company plans to expand its product offerings and enhance its market presence through new drug registrations and technology transfers[18] Accounting Standards - The new accounting standards or interpretations will be implemented starting from 2025, affecting the financial statements from the beginning of that year[28]